Clinical Trial Update: A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase Ib/II trial is evaluating GH21 capsules in combination with osimertinib for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GH21 Capsules (GH21)
• Osimertinib (osimertinib)

Snippet

Sponsor: Suzhou Genhouse Bio Co., Ltd. | Conditions: Non-Small Cell Lung Cancer With EGFR Mutation | Phase 1, Phase 2 | Status: RECRUITING